Supriya Lifescience (SUPRIYA.NS) Stock Price

Supriya Lifescience Price

NSE·CLOSED
848.95
​
Market closed

Revenue has compounded at 18.5% per year over the past 8 years to 8.28 B INR. Earnings per share have grown at 48.7% per year over the last 8 years. Supriya Lifescience's net margin stands at 25.3%, down from 29.2% several years earlier. Supriya Lifescience currently offers a dividend yield of about 0.12%. The payout ratio is around 5% of earnings. The dividend has grown at 13.6% per year over the past 4 years. Analysts set a median price target of 867.00 INR, implying 2.1% above the current price. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.

Supriya Lifescience stock price

Access this data via the Eulerpool API

Supriya Lifescience business model & stock analysis

Supriya Lifescience Ltd. supplies active pharmaceuticals ingredients (“APIs”), with a focus on research and development. The company is headquartered in Mumbai, Maharashtra and currently employs 392 full-time employees. The company went IPO on 2021-12-28. The firm is primarily engaged in manufacturing of bulk drugs and pharmaceutical chemicals. The firm exports its products in the antihistamine, anesthetics and anti-asthma therapy categories to approximately 86 countries. The firm's product portfolio consists of approximately 38 niche API products that address remedies in therapeutic segments, such as antihistamine, analgesic, vitamin, anesthetics and anti-asthmatics, among others. The firm has manufacturing facilities located in Maharashtra. Its products include Chlorphenamine Maleate, Pheniramine Maleate, Brompheniramine Maleate, Dexchlorpheniramine Maleate, Mepyramine / Pyrilamine Maleate, Dexbrompheniramine Maleate, Cetirizine DiHCL, Diphenhydramine HCL, Bisoprolol Fumarate, Nicorandil, Mecobalamin, Hydroxocobalamin Sulphate, Hydroxocobalamin Acetate, and Hydroxocobalamin Hydrochloride, among others.

Frequently asked questions about Supriya Lifescience

Analysts currently set an average price target of 867.00 INR for the Supriya Lifescience stock (median: 867.00 INR), implying +2.1 % versus the latest price. The consensus is based on 7 analyst ratings.

7 analysts currently rate the Supriya Lifescience stock: 6 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Supriya Lifescience share trades at 7.84 EUR (848.95 INR).

The Supriya Lifescience share (SUPRIYA.NS) is listed on 2 stock exchanges, including: NSE (Indien) (SUPRIYA.NS).

The revenue of Supriya Lifescience is 8.28 B INR. This figure is based on current financial data and reflects the company's business performance.

The profit of Supriya Lifescience is 2.09 B INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Supriya Lifescience is currently 32.64. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Supriya Lifescience stock.

The price-to-sales ratio (P/S) of Supriya Lifescience is currently 8.25. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Supriya Lifescience stock.

The Eulerpool Quality Score for Supriya Lifescience is 5/10.

The ISIN of Supriya Lifescience is INE07RO01027. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Supriya Lifescience is SUPRIYA.NS. The ticker symbol is used to trade Supriya Lifescience shares on the stock exchange.

Fair ValueTerminal
831.97 INR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
21.12 M INR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
INR
Initial public offering
Dec 28, 2021
ISIN
INE07RO01027
Cusip
Y83141112
Market capitalization
68.32 B INRLarge Cap
52-Week Range
PEG
1.73
P/E ratio
P/Ee 2027
28.78
P/Ee 2028
21.88
P/Ee 2029
17.12
P/S
P/Se
6.90
EV/EBIT
24.58
P/B Ratio
5.70
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
17.38 %
Dividend
Dividend yield
0.12 %
Est. Dividend Yield
0.14 %
Payout Ratio
5.02 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
4 years
Dividend not reduced since
4 years
Dividend increased since
2 years
Dividend withholding tax
20.00 %
Last updated Oct 10, 2026, 11:59 AM

Supriya Lifescience Peer Group

Supriya Lifescience Ticker

BSE · SUPRIYA.BONSE INDIA · SUPRIYA.NS

Supriya Lifescience FIGI

SUPRIYA:IN · BBG001XGYTT3SUPRIYA:IB · BBG01416VHW8SUPRIYA:IS · BBG01416VHY6